Abstract:In Chagas disease (CD), a neglected tropical disease caused by the parasite Trypanosoma cruzi , the development of mental disorders such as anxiety, depression, and memory loss may be underpinned by social, psychological, and biological stressors. Here, we investigated biological factors underlying behavioral changes in a preclinical model of CD. In T . cruzi -infected C57BL/6 mice, a kinetic study (5 to 150 days postinfection, dpi) using standardized methods revealed a sequential onset of behavioral changes: reduced innate compulsive behavior, followed by anxiety and depressive-like behavior, ending with progressive memory impairments. Hence, T . cruzi -infected mice were treated (120 to 150 dpi) with 10 mg/Kg/day of the selective serotonin reuptake inhibitor fluoxetine (Fx), an antidepressant that favors neuroplasticity. Fx therapy reversed the innate compulsive behavior loss, anxiety, and depressive-like behavior while preventing or reversing memory deficits. Biochemical, histological, and parasitological analyses of the brain tissue showed increased levels of the neurotransmitters GABA/glutamate and lipid peroxidation products and decreased expression of brain-derived neurotrophic factor in the absence of neuroinflammation at 150 dpi. Fx therapy ameliorated the neurochemical changes and reduced parasite load in the brain tissue. Next, using the human U-87 MG astroglioma cell line, we found no direct effect of Fx on parasite load. Crucially, serotonin/5-HT (Ser/5-HT) promoted parasite uptake, an effect increased by prior stimulation with IFNγ and TNF but abrogated by Fx. Also, Fx blocked the cytokine-driven Ser/5-HT-promoted increase of nitric oxide and glutamate levels in infected cells. We bring the first evidence of a sequential onset of behavioral changes in T . cruzi -infected mice. Fx therapy improves behavioral and biological changes and parasite control in the brain tissue. Moreover, in the central nervous system, cytokine-driven Ser/5-HT consumption may favor parasite persistence, disrupting neurotransmitter balance and promoting a neurotoxic environment likely contributing to behavioral and cognitive disorders. In chronic Chagas disease, illness caused by Trypanosoma cruzi infection, anxiety, depression, and memory decline are mostly related to social and psychological stressors. Here, we described the sequential onset of behavioral and cognitive changes in T . cruzi -infected mice, supporting a role for biological stressors. Indeed, in chronically infected mice, the behavioral changes parallel increased levels of the neurotransmitters GABA/glutamate and lipid peroxidation products and decreased expression of the neurotrophin BDNF. Therapy with the selective serotonin reuptake inhibitor and antidepressant fluoxetine ameliorated, prevented, or reversed behavioral and cognitive changes, improved neurochemical alterations, and, surprisingly, reduced parasite load in the brain. In vitro , serotonin fueled parasite uptake by U-87 MG cells, a human astrocyte-like cell lineage. Serotonin effects were increased by prior interferon-gamma (IFNγ) and tumor necrosis factor (TNF) stimulation but abrogated by fluoxetine and related to nitric oxide and glutamate levels in culture supernatants. Thus, the cytokine-driven consumption of serotonin may fuel T . cruzi uptake by astrocytes, sustaining brain parasitism, reducing serotonin availability, dysregulating the neurotransmitter and neurotrophin networks, and favoring a neurotoxic milieu, which may contribute to behavioral and cognitive disorders. Therefore, fluoxetine therapy, which interferes with these biological processes, may improve the quality of life of Chagas disease patients.

Shared Neuroimmune and Oxidative Pathways Underpinning Chagas Disease and Major Depressive Disorder

The End Justifies the Means: Chagas Disease from a Perspective of the Host–Trypanosoma cruzi Interaction

Novel Insights into the Mechanisms Underlying Depression-Associated Experimental Autoimmune Encephalomyelitis

Major depressive disorder as a neuro-immune disorder: Origin, mechanisms, and therapeutic opportunities

Shared Metabolic and Neuroimmune Mechanisms Underlying Type 2 Diabetes Mellitus and Major Depressive Disorder

Microbiome Alterations Driven by Trypanosoma cruzi Infection in Two Disjunctive Murine Models

Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets

Shared microglial mechanisms underpinning depression and chronic fatigue syndrome and their comorbidities

CD300f immunoreceptor is associated with major depressive disorder and decreased microglial metabolic fitness

Dysregulation of synaptic-related genes within neuroimmune networks of peripheral blood mononuclear cells in major depressive disorder

Neuroimmune Advance in Depressive Disorder

Targeting the inflammatory pathway as a therapeutic tool for major depression.

Gut microbiota–brain axis in depression: The role of neuroinflammation

Brain-immune crosstalk in the treatment of major depressive disorder

Targeting the CCL2-CCR2 axis in depressive disorders

Transcriptomic evidence of immune modulation in subjects with chronic Trypanosoma cruzi infection

Targeting Inflammatory-Mitochondrial Response in Major Depression: Current Evidence and Further Challenges

The beneficial effect of fluoxetine on behavioral and cognitive changes in chronic experimental Chagas disease unveils the role of serotonin fueling astrocyte infection by Trypanosoma cruzi

Extracellular Vesicles: Potential Role in Remote Signaling and Inflammation in Trypanosoma cruzi-Triggered Disease

Association between altered tryptophan metabolism, plasma aryl hydrocarbon receptor agonists, and inflammatory Chagas disease

Small molecule mediators of host- T . cruzi- environment interactions in Chagas disease